Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Biology Police: The Plavix Investigation and Pharmacogenomics

This article was originally published in RPM Report

Executive Summary

The discovery of a genetic marker for Plavix resistance is one of the milestones in the regulatory application of pharmacogenomics. Is it also a crime drama?

You may also be interested in...



Under DOJ’s Microscope: Teva Is Latest Company To Face Government Probe

AstraZeneca, Merck, Novartis and Sanofi are also under investigation for potential health care fraud.

Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs

HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.

The Companion Diagnostics Dilemma

An Institute of Medicine workshop on companion diagnostics suggests that regulatory standards are evolving at FDA to encourage companion diagnostic development. But almost everything else is still a challenge.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel